Abstract: This study aimed to evaluate fertility and oncologic outcomes in women with complex hyperplasia (CH) or complex atypical hyperplasia (CAH) who received fertility-sparing therapy and in vitro fertilization (IVF). Endometrial carcinoma is the most common carcinoma of the female genital tract, and is associated with endometrial hyperplasia (EH) resulting from long-term unopposed estrogenic stimulation of the endometrium. EH is characterized by non-physiological proliferation of endometrium that results in glands with irregular shapes and varying sizes. The World Health Organization (WHO) classified it into four types: simple or complex hyperplasia with or without atypia. CH is characterized by glands with irregular outlines that demonstrate marked structural complexity and back-to-back crowding. Atypical hyperplasia designates a proliferation of glands exhibiting cytologic atypia, in which varying degrees of nuclear atypia and loss of polarity are present. It has been reported that high-dose progestin is safe and efficient for CAH or early-stage low-grade carcinoma for young women who desire fertility-preserving treatment. However, few studies have reported the differences of pregnancy outcomes between patients with CAH and CH, while those patients take a great proportion in people suffered from infertility. More studies about the outcome of IVF are needed. Our aim is to evaluate fertility and oncological outcomes in women with CH or CAH who received fertility-sparing therapy.

子宫内膜不典型增生或复杂性增生不孕患者孕激素和IVF后的妊娠结局分析

[1]Chen, M., Jin, Y., Li, Y., et al., 2016. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer. Int. J. Gynaecol. Obstet., 132(1):34-38.

[2]Gadducci, A., Spirito, N., Baroni, E., et al., 2009. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option. Gynecol. Endocrinol., 25(10):683-691.

[3]Gallos, I.D., Ganesan, R., Gupta, J.K., 2013. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. Obstet. Gynecol., 121(6):1165-1171.

[4]Horn, L.C., Meinel, A., Handzel, R., et al., 2007. Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. Ann. Diagn Pathol., 11(4):297-311.

[5]Inoue, O., Hamatani, T., Susumu, N., et al., 2016. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia. Reprod. Biol. Endocrinol., 14:2.

[6]Kurman, R.J., Kaminski, P.F., Norris, H.J., 1985. The behavior of endometrial hyperplasia: a long-term study of “untreated” hyperplasia in 170 patients. Cancer, 56(2):403-412.

[7]Li, C., Bai, Y., Yan, L., et al., 2016. SPAG9 may be a potential prognostic markerof endometrial hyperplasia and grade 1 endometrioid adenocarcinoma treated with progestin. Gynecol. Obstet. Invest., 81(3):267-274.

[8]Orbo, A., Vereide, A., Arnes, M., et al., 2014. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicenter randomised trial. BJOG, 121(4):477-486.

[9]Randall, T.C., Kurman, R.J., 1997. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet. Gynecol., 90(3):434-440.

[10]Siristatidis, C., Sergentanis, T.N., Kanavidis, P., et al., 2013. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta-analysis. Hum. Reprod. Update, 19(2):105-123.

[11]Stubert, J., Gerber, B., 2016. Current issues in the diagnosis and treatment of endometrial carcinoma. Geburtsh. Frauenheilk., 76(2):170-175.

[12]Yang, Y.F., Liao, Y.Y., Liu, X.L., et al., 2015. Prognosticfactors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment. Gynecol. Oncol., 139(3):419-423.

[13]Zhou, R., Yang, Y., Lu, Q., et al., 2015. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients. Gynecol. Oncol., 139(3):424-428.